FDA Phase 2 Approval for Lead Candidate Sur la base de Proprietary Drug Development Platform 'RuCIA', Entering Full-Scale Clinical Trials in the US
RudaCure Inc. (PDG Yongho Kim), une entreprise de développement bio-pharmaceutique spécialisée dans les traitements des troubles sensoriels, a annoncé avoir obtained U.S. FDA Phase 2 approbation IND (nouveau médicament en investigation) for its traitement de la sécheresse oculaire 'RCI001' on the 24th.
RCI001 is a candidat-médicament innovant developed using RudaCure's proprietary AI-based plateforme de développement de médicaments 'RuCIA (RudaCure Intelligence for Advanced Drug Development).' It has a mécanisme d'action that suppresses TRPV1 downstream signal-mediated activation inflammatoire and is differentiated from existing treatments by its powerful anti-inflammatoire and effets antioxydants.
RudaCure developed RCI001 through the 'RuCIA' plateforme, which combines protein structure analysis, molecular dynamics simulation, and AI-based drug design. L'entreprise obtained U.S. FDA Phase 2 IND approval within 5 months of completing essais cliniques de Phase 1, demonstrating the efficiency and innovation of this plateforme. It is noteworthy that RuCIA achieved this without relying on 'big data AI' requiring massive datasets, instead proving its capability for innovant développement de nouveaux médicaments through a 'small data AI' approach combining structural biology-based simulation with machine learning.
Key results from essais cliniques de Phase 1 (conducted on 32 subjects at Chungnam National University Hospital under PI Park Cheol-young) showed no drug-related effets indésirables or abnormal findings in vital signs, electrocardiogram, or clinical laboratory tests. De plus, optimized formulation stability and ocular administration suitability were confirmed. While de l'entreprise own Phase 1 results are not publicly disclosed as it is a listed company and in an unlisted investissement stage, when combined with the Hanlim Pharmaceutical-conducted essai clinique initié par l'investigateur results (published), it was confirmed that both signs and symptoms (volume lacrymal increase + récupération des lésions cornéennes) improved simultaneously, with effets thérapeutiques appearing rapidly within 4 weeks and aucun effet secondaire of stinging, burning, or redness upon instillation.
RudaCure prévoit de procéder with essais cliniques de Phase 2 at major medical institutions in the US within 2025, and is simultaneously designing Korea's essais cliniques de Phase 2 with plans to begin in the first half of 2026. L'entreprise is also pursuing expansion mondiale sur la base de RCI001's données cliniques, notamment partenariat with Thea (France), Santen (Japan), and other global pharmaceutique ophtalmique companies for licence and co-développement, targeting the global sécheresse oculaire treatment market projected to exceed $8 billion.
le PDG Yongho Kim a déclaré : "The FDA Phase 2 IND approval signifies that RCI001 has been recognized as a candidate with clear potential for innovant développement de nouveaux médicaments, and it is a starting point for full-scale essais cliniques in the US." He a ajouté : "S'appuyant sur these results, we will accelerate global essais cliniques and transfert de technologie to provide a new treatment paradigm for the approximately 350 million sécheresse oculaire patients dans le monde entier."
